Asieris Appoints Dr. Linda Wu as Chief Development Officer
SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.
- SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Linda Wu, Ph.D. will join Asieris as Chief Development Officer today, effective January 17, 2023.
- Dr. Wu will be based in the United States and report to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris.
- Dr. Wu joins Asieris from Janssen Pharmaceuticals, a Johnson & Johnson company, where she most recently served as a Group Medical Director of Oncology, US Medical Affairs.
- "I am thrilled and deeply honored to be appointed as Chief Development Officer at Asieris.